Capricor Therapeutics Inc (NASDAQ: CAPR) has reported E.P.S. of $-0.16 for its fourth fiscal quarter (ending December 31) versus $-0.02 for the same period a year ago — an increase of 700%. For the latest four quarters through December 31, E.P.S. were $-1.15 compared to $-0.83 a year ago — an increase of 39%.
Recent Price Action
Capricor Therapeutics Inc (NASDAQ: CAPR) stock closed at $12.22 on 3/19/25 after a very large increase of 5.3%. NORMAL trading volume accompanied the advance. The stock has declined -2.9% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Capricor Therapeutics has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Capricor Therapeutics has a very low Appreciation Score of 2 but a very high Power Rating of 92, resulting in the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment